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ATP-dependent K+ channelsNicorandil (2-nicotinamide ethyl nitrate), an antianginal drug characterized by the coupling of nicotinamide
with a nitric oxide (NO) donor, activates guanylyl cyclase and opens ATP-dependent K+ channels. In the
present study, we investigated the effects induced by per os (p.o.) administration of nicorandil (12.5, 25 or
50 mg/kg) or equimolar doses (corresponding to the highest dose of nicorandil) of N-(2-hydroxyethyl)
nicotinamide (NHN), its main metabolite, or nicotinamide in the model of nociceptive response induced by
formaldehyde in mice. Nicorandil, but not NHN or nicotinamide, inhibited the second phase of the nocicep-
tive response. This activity was observed when nicorandil was administered between 30 and 120 min before
the injection of formaldehyde. Ipsilateral intraplantar injection of nicorandil (125, 250 or 500 μg/paw) did
not inhibit the nociceptive response. After p.o. administration of nicorandil (50 mg/kg), peak plasma concen-
trations of this compound and NHN were observed 0.63 and 4 h later, respectively. Nicotinamide concentra-
tions were not increased after administration of nicorandil. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
(ODQ; 1 or 2 mg/kg), a guanylyl cyclase inhibitor, partially attenuated the antinociceptive activity of
nicorandil. However, this activity was not changed by glibenclamide (30 or 60 mg/kg), an inhibitor of
ATP-dependent K+ channels. In conclusion, we demonstrated the antinociceptive activity of nicorandil in a
model of pain that exhibits both a nociceptive and an inﬂammatory proﬁle. This activity is not mediated by
nicotinamide or NHN. The coupling of an NO-donor to nicotinamide results in a compound with an increased
potency. The NO–cGMP pathway, but not ATP-dependent K+ channels, partially mediates the antinociceptive
activity of nicorandil.
© 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Discovering new functions of drugs already used in the clinic is
among the different and important strategies that have been promoted
to optimize the development of new and safe pharmacotherapies, with
lower costs and in a shorter period of time (Ashburn and Thor, 2004).
B vitamins, traditionally used to correct nutritional deﬁciencies, exhibit
analgesic and anti-inﬂammatory properties when administered in pa-
tients with neuropathic disorders (Jörg et al., 1988), premenstrual ten-
sion (Wyatt et al., 1999) and carpal tunnel syndrome (Folkers et al.,
1984) and are useful in migraine prophylaxis (Boehnke et al., 2004;
Schoenen et al., 1998). Expectedly, B vitamins, including thiamine,
pyridoxine and riboﬂavin, also induce effects in different experimental
models of pain and inﬂammation (Bertollo et al., 2006; Bartoszyk and
Wild, 1990; França et al., 2001; Zimmermann et al., 1990). In addition,Coelho).
vier OA license.another member of the B vitamin family, nicotinamide, suppresses ar-
thritis and inhibits the phagocytic generation of reactive oxygen species
in an experimental model of arthritis (Miesel et al., 1995), the paw
edema andmechanical allodynia induced by carrageenan and the noci-
ceptive response induced by formaldehyde and heat in rodents (Godin
et al., 2011).
Nicorandil, a nicotinamide nitrate derivative (2-nicotinamide ethyl
nitrate; Fig. 1), is a nitric oxide (NO) donor approved for the treatment
of patients with angina pectoris (El-Moselby et al., 2009; Frampton et
al., 1992). In addition to releasing NO, nicorandil may be converted in
vivo to N-(2-hydroxyethyl)-nicotinamide (NHN, Fig. 1), the main me-
tabolite (César et al., 2011; Frydman et al., 1989), and also nicotinamide
(Frydman et al., 1989). NO-donors have been used to treat patients
with angina due to their vasodilator properties, but it has been ac-
knowledged that an intrinsic analgesic activity associated with the re-
lease of NO is also involved (Ferreira et al., 1992; Soares et al., 2000).
It has been demonstrated that NO-donors induce antinociceptive
and anti-hyperalgesic effects in different experimental models of pain,
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Fig. 1. Chemical structures of nicorandil (A), NHN (B) and nicotinamide (C).
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location (Duarte et al., 1990; Soares et al., 2000; Sousa and Prado,
2001). The demonstration of the antinociceptive and anti-hyperalgesic
activities of NO donors contributed to the search for new compounds
with fewer side effects and greater efﬁcacy such as the NO-releasing
steroidal and non-steroidal anti-inﬂammatory drugs (Galassi et al.,
2006; Keeble and Moore, 2002). Regarding nicorandil, it has been
shown that its central administration,while not inducing antinociception
per se, exacerbates the antinociceptive effect induced by morphine, fen-
tanyl, bethanechol and clonidine in experimental models of nociceptive
pain induced by heat in rats (Asano et al., 2000; Yamazumi et al., 2001).
In the present study, we investigated the effects induced by
systemic administration of nicorandil in the experimental model of
pain induced by formaldehyde in mice, a model that exhibits both
a nociceptive and an inﬂammatory proﬁle. We also investigated
whether the activity of nicorandil is mediated by biotransformation
to nicotinamide or NHN and involves activation of guanylyl cyclase
and ATP-dependent potassium channels.
2. Materials and methods
2.1. Animals
Male Swissmice (25–30 g)were used andhad free access to food and
water. The animals were kept in a room with 12 h light–dark cycle and
temperature of 27 °C, which corresponds to the thermoneutral zone
for rodents, for at least 3 days before the experiment to allow acclimati-
zation. This study was approved by the Ethics Committee on Animal
Experimentation of the Federal University of Minas Gerais (Protocol
131/11) and all experiments were conducted according to the ethical
guidelines for investigation of experimental pain in conscious animals
(Zimmermann, 1986).
2.2. Drugs
Nicorandil and NHN, both with purity >99.0%, were synthesized at
the Department of Chemistry, Federal University of Minas Gerais. Nico-
tinamide, glibenclamide, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
(ODQ), and dipyrone sodiumwere purchased from Sigma, USA. Pheno-
barbital was purchased from Aventis Pharma, Brazil. Nicotinamide
and dipyrone solutions were prepared in saline. The suspensions of
nicorandil, NHN and phenobarbital for per os (p.o.) administration
were prepared in carboxymethylcellulose (CMC; 0.5% w/v in saline).
The suspension of nicorandil for local administration (intraplantar,
i.pl.) was prepared in 2% dimethyl sulfoxide (DMSO). The suspensions
of glibenclamide and ODQ were prepared in 1% CMC and 4% DMSO,
respectively. The solutions of formaldehyde (0.92 or 1.84%) were pre-
pared in saline. All solutions or suspensionswere prepared immediately
before each experiment.
2.3. Evaluation of the nociceptive response induced by formaldehyde
On the experiment day, the animals were placed under glass
funnels (18 cm diameter and 14 cm high) about 30 min before injec-
tion of formaldehyde to allow acclimatization. Formaldehyde (0.92%,20 μl) was injected subcutaneously (s.c.) into the dorsal surface of the
right hindpaw of the animals. In the protocol used to investigate the
effect induced by local injection of nicorandil or dipyrone, a volume
of 10 μl of 1.84% formaldehyde solution was used. The amount of
time that the animal licked the injected paw was measured 0–5 min
and 15–30 min after the injection of formaldehyde, corresponding to
the ﬁrst and second phases of the nociceptive response, respectively
(Tjølsen et al., 1992).
In most of the protocols, nicorandil was administered p.o. 60 min
before the injection of formaldehyde. However, in one protocol aimed
to assess the duration of its effect, nicorandil was administered at dif-
ferent times (30, 60, 120, 180 or 240 min) before the administration
of formaldehyde. NHN and nicotinamide were administered p.o.
60 min before the injection of formaldehyde. ODQ (intraperitoneal,
i.p.) and glibenclamide (p.o.) were administered 30 and 60 min, re-
spectively, before nicorandil. To investigate the effects induced by
local injection of nicorandil or dipyrone, these drugs were adminis-
tered i.pl. 20 min before the injection of formaldehyde. The animals
were carefully monitored during the interval between administration
of nicorandil and injection of formaldehyde to evaluate whether the
local injection of nicorandil could induce a behavior indicative of
discomfort.2.4. Evaluation of the motor activity
A rota-rod apparatus was used to evaluate the motor activity of the
animals. The animals were trained on the apparatus for 3 days before
the experiment. On the experimental day, the animals were placed on
the rota-rod (14 rpm) and the time they spent on it was measured.
The cut-off time was 2 min. After determination of the baseline values,
the animals were treatedwith nicorandil (50 mg/kg, p.o.) or phenobar-
bital (40 mg/kg, p.o.) and 60 min later they were again tested in the
apparatus.2.5. Quantiﬁcation of nicorandil, NHN and nicotinamide in plasma by
liquid chromatography–electrospray ionization tandemmass spectrometry
(LC–ESI-MS/MS)
The methods used for the quantiﬁcation of nicorandil, NHN and
nicotinamide were developed and validated by César et al. (2011).
The mobile phase consisted of methanol and aqueous ammonium ac-
etate containing 2 mM formic acid 0.03% (v/v) (33:67 v/v) in the ﬂow
rate of 1 ml/min. The injection volume was 50 μl. The linear ranges of
concentrations were: 25–75 μg/ml (nicorandil), 25–50 μg/ml (NHN)
and 25–10 μg/ml (nicotinamide).
For the pharmacokinetic study, we used animals submitted to food
restriction for 6 h. Nicorandil was administered p.o. at a dose of
50 mg/kg to 44 animals. At different times (5, 15, 30 and 45 min, 1,
2, 3, 4, 6, 8 and 10 h) after administration of nicorandil, a group of
four animals were euthanized by decapitation after anesthesia by
halothane. Twelve additional animals received an injection of vehicle.
These animals, in groups of four, were euthanized immediately before
and 30 and 60 min after injection of the vehicle. A blood sample from
each animal was collected in a heparinized tube and immediately
Fig. 3. Effect induced by nicorandil (50 mg/kg, p.o.) administered at different times
(−0.5,−1,−2,−3 or−4 h) on the nociceptive response induced by formaldehyde.
* and ** indicate statistically signiﬁcant difference compared to the vehicle treated
group at the respective times (p b 0.05 and p b 0.01, respectively). n = 6–8.
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transferred to plastic tubes and stored at −70 °C until analysis.
2.6. Statistical analysis
Two or three observers, that were not aware of the treatments,
evaluated the nociceptive behavior in the different experimental pro-
tocols. Results were expressed as mean ± standard error of mean.
Data were analyzed by one-way ANOVA, followed by Newman–
Keuls test or Student's t test. For dose–response curves one-way
ANOVA and subsequent linear regression ANOVA were performed. A
p b 0.05 was considered signiﬁcant.
3. Results
3.1. Effects induced by p.o. administration of nicorandil or equimolar
doses of NHN or nicotinamide on the nociceptive response induced by
formaldehyde
Nicorandil, at the dose of 50 mg/kg, inhibited the second phase of
nociceptive response induced by formaldehyde. However, equimolar
doses of nicotinamide or the metabolite NHN (Fig. 2) did not inhibit
this response. The effects induced by lower doses of nicorandil (12.5
and 25 mg/kg) were also evaluated. Although the dose of 25 mg/kg
partially inhibited the nociceptive response, this reduction was not
statistically signiﬁcant (Fig. 2).
To investigate whether the inhibition of the nociceptive behavior
induced by nicorandil is not the result of a motor impairment, we
evaluated the effect induced by the drug on the performance of the
animals on the rota-rod apparatus. Nicorandil (50 mg/kg) did not
alter the time mice spent in the apparatus, while phenobarbital
(40 mg/kg) markedly reduced this parameter (data not shown).
To assess the duration of the effect induced by nicorandil and also
to evaluate if there is a relation between the antinociceptive effect
induced by the drug and its pharmacokinetic proﬁle, a protocol in
which the drug was administered at different times before the admin-
istration of formaldehyde was carried out. Nicorandil inhibited the
ﬁrst phase of the nociceptive response only when administered
30 min prior to administration of the nociceptive stimulus. The sec-
ond phase of the nociceptive response induced by formaldehyde
was inhibited when nicorandil was given 30, 60 or 120 min before.
On the other hand, the administration of nicorandil 3 or 4 h before
the administration of formaldehyde did not inhibit the nociceptive
response (Fig. 3).
3.2. Plasma concentrations of nicorandil, NHN and nicotinamide after
p.o. administration of nicorandil
After administration of nicorandil (50 mg/kg), peak plasma con-
centrations of the drug and its primary metabolite, NHN, were
found 0.63 and 4 h, respectively (Fig. 4). The plasma concentrationsFig. 2. Effect induced by nicorandil (12.5, 25 or 50 mg/kg, p.o., −60 min) or a dose
of nicotinamide or NHN (equimolar to 50 mg/kg of nicorandil, p.o., −60 min) on the
nociceptive response induced by formaldehyde. n = 6–8. * indicates statistically signiﬁ-
cant difference compared to the vehicle treated group (p b 0.05).of nicorandil between 30 and 120 min after its administration ranged
from 20 to 25 μg/ml. As the drug induced an antinociceptive effect
when administered 30 to 120 min before the injection of formaldehyde,
this effect was associated with the highest plasma concentrations of
nicorandil. On the other hand, the concentrations of nicotinamide
ranged between 1.4 and 3.3 μg/ml after administration of nicorandil
and did not differ from that observed in the plasma of untreated
animals.
From the analysis of the results presented in Fig. 4, some pharma-
cokinetic parameters were calculated for nicorandil and NHN. These
parameters included maximum plasma concentration, time to reach
maximum concentration (Tmax) and elimination half-life (T1/2) and
are shown in Table 1.
3.3. Effect induced by i.pl. administration of nicorandil on the nociceptive
response induced by formaldehyde
To evaluatewhether the antinociceptive effect induced by nicorandil
could be the result of an action at the peripheral site where the noxious
stimulus was injected, the drug was administered via the i.pl. route at
the doses of 125, 250 or 500 μg/paw, 20 min before the injection of
formaldehyde. The i.pl. administration of nicorandil failed to inhibit
the nociceptive response induced by formaldehyde (Fig. 5). The animals
were carefully monitored during the interval between i.pl. administra-
tion of nicorandil or vehicle and the injection of formaldehyde, leading
to the conclusion that the i.pl. injection of nicorandil, per se, does not in-
duce a behavior indicative of discomfort (licking or shaking the injected
paw). The nociceptive response induced by formaldehyde may be
inhibited by the local action of drugs, as conﬁrmed by the demonstration
that previous (20 min) ipsilateral, but not contralateral, administration
of dipyrone (200 μg/paw) inhibited this response (data not shown).Fig. 4. Plasma concentrations of nicorandil, NHN and nicotinamide observed after
administration of nicorandil (50 mg/kg, p.o.). n = 4 at each point.
Table 1
Maximum concentration, time for maximum concentration (T max) and elimination
half-life (T 1/2) of nicorandil and NHN after p.o. administration of nicorandil (50 mg/kg).
Maximum concentration (μg/ml) Tmax (h) T1/2 (h)
Nicorandil 30.92 ± 9.64 0.63 ± 0.32 1.06 ± 0.48
NHN 16.82 ± 3.63 4.00 ± 1.41 1.45 ± 0.50
Fig. 6. Effect induced by nicorandil (50 mg/kg, p.o., −60 min) on the nociceptive re-
sponse induced by formaldehyde in animals previously (60 min) treated with vehicle
or glibenclamide (30 or 60 mg/kg, p.o.). ** and *** indicate statistically signiﬁcant differ-
ence compared to vehicle treated group (p b 0.01 and p b 0.001, respectively). n = 7–8.
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activity of nicorandil
The administration of glibenclamide (30 or 60 mg/kg; p.o.),
60 min before the p.o. administration of nicorandil (50 mg/kg), did
not affect its antinociceptive activity (Fig. 6). On the other hand,
the antinociceptive activity of nicorandil (50 mg/kg) was partially
attenuated in the animals previously (30 min) treated with ODQ
(2 mg/kg; i.p.) (Fig. 7).
4. Discussion
Central administration of nicorandil, while not inducing
antinociception per se, exacerbates the antinociceptive effect induced
by morphine, fentanyl, bethanechol and clonidine in rodents (Asano
et al., 2000; Yamazumi et al., 2001). In the present study, we demon-
strated that systemic administration of nicorandil per se induces an
antinociceptive effect in an experimental model of pain that exhibits
both a nociceptive and an inﬂammatory proﬁle. The nociception in-
duced by formaldehyde results from the fast activation of the transient
receptor potential channels TRPA1 (McNamara et al., 2007) and TRPV1
(Tian et al., 2009) and also the inﬂammation following the tissue damage
(Hunskaar and Hole, 1987; TjøLsen et al., 1992). Excepting the protocol
in which the administration occurred 30 min before formaldehyde,
nicorandil inhibited only the second phase of the nociceptive response.
Thus, its proﬁle resemblesmore that of anti-inﬂammatory drugs such as
indomethacin (Morgan et al., 1992) and diclofenac (León-Reyes et al.,
2009). It is unlikely that the inhibitory effect induced by nicorandil on
the nociceptive behavior results from muscle relaxing effect or motor
incoordination, as the drug did not reduce the time that the animals
spent in the rota-rod.
As nicorandil represents a coupling of nicotinamidewith anNOdonor,
some suggestionsmay be put forward to explain its antinociceptive activ-
ity. These include (1) an indirect antinociceptive effect induced by nico-
tinamide, a compound that exhibits antinociceptive activity (Godin et
al., 2011) and can be formed from nicorandil in vivo (Frydman et al.,
1989); (2) an indirect antinociceptive effect induced by NHN, the
nicorandil main metabolite (Frydman et al., 1989; César et al., 2011);
(3) an indirect antinociceptive effect induced by NO, as nicorandil has
the ability to release NO (Lefer and Lefer, 1988; Sakai et al., 2000) and
NO donor drugs exhibit antinociceptive activity (Duarte et al., 1990;
Sousa and Prado, 2001); (4) an antinociceptive effect induced directlyFig. 5. Effect induced by ipsi or contralateral administration of nicorandil (125, 250 or
500 μg/paw, i.pl., −20 min) of the nociceptive response induced by formaldehyde.
n = 6–7.by nicorandil; and (5) an antinociceptive effect resulting froma combina-
tion of two or more of the suggested mechanisms.
The ﬁrst suggestion, i.e., the antinociceptive activity of nicorandil
resulting from the action of nicotinamide, is unlikely as it was not
associated with an increase of the plasma concentrations of the last
compound. Furthermore, equimolar doses of nicotinamide did not
induce an antinociceptive effect. Previously, using the same experi-
mental model, we demonstrated that nicotinamide, at the dose of
1000 mg/kg, but not at the doses of 125, 250 or 500 mg/kg, exhibited
antinociceptive activity (Godin et al., 2011). As nicorandil induced an
antinociceptive effect at the dose of 50 mg/kg, its potency is about 34
times higher than that of nicotinamide.
Regarding the second suggestion, i.e., the antinociceptive activity of
nicorandil resulting from the action of NHN, the results of the present
study also indicate that it is highly unlikely. Equimolar doses of NHN
did not induce an antinociceptive effect and there is also amismatch be-
tween its plasma concentrations after nicorandil administration and the
antinociceptive effect induced by the last drug. The highest concentra-
tions of NHNwere observed between 3 and 5 h after nicorandil admin-
istration while this last drug only inhibited the nociceptive response
when administered between 30 and 120 min before the injection of
formaldehyde.
The third suggestion, an indirect antinociceptive effect resulting
from the action of NO, may also be put forward to explain the activity
of nicorandil. The results of the present study provided mixed cues.
Assuming that the formation of NHN is paralleled with the formation
of NO, once again, a mismatch is observed between the antinociceptive
activity and formation of NO. On the other hand, the previous adminis-
tration of ODQ, an inhibitor of guanylyl cyclase, partially attenuates
the antinociceptive activity of nicorandil. It has been shown that this
enzyme catalyses the formation of cGMP, a signalingmolecule that me-
diates many effects induce by NO (Duarte et al., 1990; Jain et al., 2001).Fig. 7. Effect induced by nicorandil (50 mg/kg, p.o., −60 min) on the nociceptive
response induced by formaldehyde in animals previously (30 min) treated with vehi-
cle or ODQ (1 or 2 mg/kg, i.p.). * and ** indicate statistically signiﬁcant difference
compared to vehicle–vehicle treated group (p b 0.05 and p b 0.01, respectively). # in-
dicates statistically signiﬁcant difference compared to vehicle–nicorandil treated group
(p b 0.05). n = 7–8.
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possibility is likely, not only because the main metabolites of nicorandil
do not exhibit antinociceptive activity (NHN and nicotinamide) or have
a partial role (NO), but also because there is a good relationship be-
tween the effect induced by nicorandil and its plasma concentrations,
thatweremaximal between60 and 120 min, declining thereafter. Coin-
cidentally, nicorandil induced an antinociceptive effect when adminis-
tered 30 to 120 min before injection of formaldehyde, and this effect
was reduced or absent when the drugwas administered 3 or 4 h before
the noxious stimulus. The pharmacokinetic proﬁle of nicorandil in mice
is similar to that observed in rats. Tmax values for mice and rats (César et
al., 2011)were 0.63 and0.46 h, respectively.Moreover, the values of T1/2
for mice and rats (César et al., 2011) were 1.1 and 1.9 h, respectively.
We also investigated whether the antinociceptive effect induced
by nicorandil could be the result of an action at the peripheral site
where the noxious stimulus was injected. Some NO donors induce
an antinociceptive effect by activating peripheral mechanisms. Topi-
cal application of nitroglycerin to the paw attenuates the mechanical
hyperalgesia induced by i.pl. injection of prostaglandin E2 (PGE2) and
reduces the neurogenic inﬂammatory edema induced by electrical
stimulation in rats (Ferreira et al., 1992). Furthermore, intra-articular or
i.pl. administration of sodium nitroprusside induces an antinociceptive
effect in a model of arthritis induced by zymosan (Rocha et al., 2002)
and attenuates the hyperalgesia induced by i.pl. injection of PGE2
(Alves et al., 2004a) in rats, respectively. As i.pl. injection of nicorandil
failed to induce an antinociceptive effect, its activity after p.o. administra-
tion may be the result of an action at other sites. Although differences in
animal species and experimental models used may help to explain the
different results, there is evidence that nicorandil, despite being an NO
donor, exhibits many differences when compared to other drugs that
also release NO, particularly organic nitrates.
Regarding the cardiovascular actions of nicorandil, those that have
been investigated more extensively, it is concluded that this drug
exhibits important differences when compared to the traditional
organic nitrates, possibly due to its ability of opening potassium chan-
nels, an activity that appears to be linked to the nicotinamide portion
of the molecule (Edwards and Weston, 1990; Taira, 1987).Greenberg
et al. (1991), investigating the effects induced by nicorandil and
traditional organic nitrates (nitroglycerin, isosorbide dinitrate, 2-
isosorbide mononitrate, 5-isosorbide mononitrate), demonstrated that
nicorandil relaxes different canine blood vessels equieffectively with
the traditional organic nitrates but with smaller maximal increases in
cGMP. These results indicate that despite being less efﬁcient as an acti-
vator of guanylyl cyclase when compared to the traditional organic
nitrates, the vasodilator activity of nicorandil is not reduced. In addition,
depending on the rat vascular bed analyzed, the vasodilator activity of
nicorandil may be associated with activation of guanylyl cyclase or
opening of potassium channels. However, in porcine artery prepara-
tions, the vasodilator effect is associated with the two mechanisms
simultaneously (Borg et al., 1991). These results indicate the complexity
of mechanistic pathways associated with the vasodilator activity of
nicorandil, a drug that, in spite of being an NO donor, differs markedly
in relation to the traditional organic nitrates.
In spite of differences related to vascular beds, oxygen levels and na-
ture of contracting agonists used (Dumas et al., 1996; Pérez-Vizcaíno et
al., 1998; Cogolludo et al., 1999), the vasodilation induced by nicorandil
is usuallymediated by activation of soluble guanylyl cyclase and opening
of ATP-dependent potassium channels. Thus, we investigated whether
these putative biochemical mechanisms could also contribute to the
antinociceptive activity of nicorandil. To accomplish this objective, we
investigatedwhether glibenclamide, an ATP-dependent potassium chan-
nel blocker (Alves et al., 2004b), and ODQ, a guanylyl cyclase inhibitor
(Boulton et al., 1995; Garthwaite et al., 1995), could affect the
antinociceptive activity of nicorandil. It is known that the antinociceptive
activity of various drugs, coupled or not with NO donors, is reversed by
guanylyl cyclase inhibitors and ATP-dependent potassium channelblockers (Duarte and Ferreira, 1992; Duarte et al., 1992; Ferreira et
al., 1991; Prado et al., 2002).
Previous administration of ODQ partially attenuated the
antinociceptive effect induced by nicorandil. However, glibenclamide
failed to affect the antinociceptive activity of nicorandil. It is unlikely
that the doses of glibenclamide used in the present study were low,
as Ortiz (2011) have shown that much lower doses of glibenclamide
(3 or 10 mg/kg) inhibit the antinociceptive effect induced by diclofenac
(30 mg/kg) in the model of nociceptive response induced by formalde-
hyde. Altogether, these results indicate that the activity of nicorandil in
the model used in the present study partially involves the activation
of guanylyl cyclase, but not ATP-dependent potassium channels. They
also provide support to the suggestion that besides the ODQ- and
glibenclamide-sensitive mechanisms, other mechanisms mediate the
antinociceptive effects induced by nicorandil.
In conclusion, systemic administration of nicorandil induces an
antinociceptive effect in an experimental model of pain that exhibits
both a nociceptive and an inﬂammatory proﬁle. Considering pharma-
cokinetic data and pharmacological activity, it is highly unlikely that
the antinociceptive activity of nicorandil is mediated by nicotinamide
or NHN. The partial involvement of guanylyl cyclase, but not ATP-
dependent potassium channels, is suggested. The demonstration of
the antinociceptive activity of nicorandil may contribute to raise the
interest in the clinical evaluation of its usefulness in the treatment
of patients with painful disorders and, ultimately, result in a new
drug repositioning.
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